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ABSTRACT 
Measles is a contagious, vaccine-preventable disease that continues to be the leading 
cause of death in children younger than the age of 5 years. While the introduction of the Measles, 
Mumps, and Rubella vaccine (MMR) has significantly decreased morbidity and mortality rates 
worldwide, vaccine coverage is highly variable across global regions. Current diagnostic methods 
rely on enzyme immunoassays (EIA) to detect IgM or IgG Abs in serum. Commercially available 
Diamedix Immunosimplicity® Measles IgG test kit has been shown to have 91.1% sensitivity and 
93.8% specificity, with a positive predictive value of 88.7% and a negative predictive value of 
90.9% on the basis of a PRN titer of 120. There is an increasing need for rapid screening for 
measles specific immunity in outbreak settings. This study aims to develop a rapid molecular 
diagnostic assay to detect IgG reactive to three individual measles virus (MeV) proteins.  
Measles virus (MeV) genes were subcloned into the pJFT7_nGST vector to generate N-
terminal GST fusion proteins. Single MeV cistrons were expressed using in vitro 
transcription/translation (IVTT) with human cell lysate. Expression of GST-tagged proteins was 
measured with mouse anti-GST mAb and sheep anti-mouse IgG. Relative light units (RLUs) as 
luminescence was measured. Antibodies to MeV antigens were measured in 40 serum samples 
from healthy subjects. 
Protein expression of three MeV genes of interest was measured in comparison with 
vector control and statistical significance was determined using the Student’s t-test (p<0.05). N 
expressed at the highest level with an average RLU value of 3.01 x 109 (p<0.001) and all proteins 
were expressed at least 50% greater than vector control (4.56 x 106 RLU). 36/40 serum samples 
had IgG to N (Ag:GST ratio>1.21), F (Ag:GST ratio>1.92), or H (Ag:GST ratio> 1.23).  
These data indicate that the in vitro expression of MeV antigens, N, F, and H, were 
markedly improved by subcloning into pJFT7_nGST vector to generate N-terminal GST fusion 
proteins.	The expression of single MeV genes N, F and H, are suitable antigens for serologic 
capture analysis of measles-specific antibodies.	These preliminary data can be used to design a 
more intensive study to explore the possibilities of using these MeV antigens as a diagnostic 
marker. 
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1. INTRODUCTION 
The Measles virus (MeV) is a contagious pathogenic virus that is associated with 
complications such as encephalitis and pneumonia (1). The measles, mumps, rubella vaccine 
(MMR vaccine) was introduced over fifty years ago and has led to an overall decline of measles 
incidence, yet MeV is still a major cause of death in children in developing countries (2). Even 
with global vaccination rates over 84% (3), there have been numerous outbreaks in recent years 
(2) due to the contagious nature of MeV. In 2014, there were over 16 deaths every hour due to 
MeV infections, with a total of 145,000 deaths globally (4). Worldwide, over 21.5 million children 
were not vaccinated against MeV in 2013 (5). In 2014 alone the United States had 23 MeV 
outbreaks, and in 2011, 30 countries reported an increase in measles incidence (6). In 2015, a 
recent measles outbreak in a theme park had spread to over seven different states, 
encompassing about 113 cases. During the first 6-month period of 2016, there were over 100,000 
suspected cases of MeV worldwide, with only about 14,000 of those cases being laboratory 
confirmed (7). 
MeV is a member of the Morbivillivirus genus in the Paramyxoviridae family (8). It is 
enveloped, spherical, non-segmented and contains single stranded, negative sense RNA. The 
MeV antigenome includes eight proteins (Figure 1) with six ORFs encoded by approximately 
16,000 nucleotides (9).  
 
Figure 1. Diagram of Measles Virus antigenome. Measles virus contains eight proteins encoded 
by 16,000 nucleotides (9). 
 
 
Three MeV genes of interest for this study are: nucleoprotein, fusion protein, and 
hemagglutinin (N, F, and H). Infection by MeV is initiated on vulnerable cells by the components 
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present on the viral envelope. Transmembrane proteins, H and F, are found on the viral envelope 
(8). The antibodies (Abs) for these transmembrane proteins are able to deactivate the infectious 
activity of MeV (10). The genomic RNA is surrounded by a nucleocapsid, which forms the 
ribonucleocapsid (10). F fuses the viral envelope of MeV with the cellular plasma membrane of 
the cell to be infected (10). Infected cells express H and F on its cell surface. This allows for 
receptor binding by H to the surfaces of nearby cells, triggering the fusing activity of the F. 
Eventually, this results in the formation of giant cells (10). N aids in packing the MeV genome into 
a ribonucleoprotein complex (11). MeV is spread through direct contact with respiratory 
secretions within droplets from infected individuals (12). Droplets that contain MeV can survive in 
the environment for several hours (12). 
Measles outbreaks have been linked to the decrease in vaccine uptake over the years 
(13). Numbers of MeV cases in the United States has been steadily increasing since 2010, with a 
peak in the number of cases in 2014 (6) when a large outbreak occurred in an unvaccinated 
Amish community that included over 383 cases. The pattern of decreasing vaccine uptake can 
lead to the re-establishment of endemic measles along with an increase in measles mortality 
rates. The primary reason for increased number of measles cases and transmission of measles is 
due to failure to vaccinate populations which are susceptible, especially those in Europe. In 2000, 
the United States had achieved complete elimination of measles due to high vaccination rates 
(14) (15). But, the potential risk of outbreaks still exist as importation of MeV from foreign 
countries still occurs (16) and MeV is brought into the United States by unvaccinated travelers. 
The vaccination rate for the MMR vaccine in 2013 was below 91% in over 17 states (17). 
MeV increases susceptibility to other diseases and about 30% of MeV cases have 
complications (18), including diarrhea, otitis media, pneumonia, encephalitis, and seizures. The 
best method for prevention of MeV is the measles vaccine, which provides active immunization 
against MeV (8). This vaccine can be administered to children over the age of 9 months (19). The 
MMR vaccine is an attenuated strain of MeV taken from the wild type virus. The vaccine is not 
linked with immunosuppression, but it does provide long-term immunity (10). MeV is still 
considered endemic worldwide and rapid confirmation of MeV is imperative in outbreak settings.  
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One dose of the MMR vaccine is 95% effective at preventing MeV, and two doses of 
MMR vaccine are about 99% effective MeV (20). Between 2-5% do not develop MeV immunity 
after the first dose of the vaccine (20). The first dose of MMR vaccine is given around 12 months, 
after loss of passive protection from breast milk, and the second dose is administered at least 28 
days after the first dose (21) up until 4-6 years of age. People who have received two doses of 
the MMR vaccine are considered to have life-long immunity and do not need a booster dose. 
However, adults may require a booster dose in the event that they do not present evidence of 
immunity (22). Adults that are traveling to places with high risk of MeV transmission need to 
ensure that they have had two doses of MMR administered at least 28 days apart. MMR vaccine 
is effective if administered to patients within the first 72 hours after exposure to MeV (20). 
MeV vaccine has a failure rate of 2 to 10%, leading to the implementation of the second 
dose policy (23). Seropositivity has been shown to be 95%, 74%, and 100% for MeV, mumps, 
and rubella, respectively, for 183 initial seronegative vaccinees 15 years after the second 
administration of MMR vaccine (24). Geometric mean level of Abs to MeV showed a decline from 
1917 to 957 to 729 mIU/mL during the 15-year study, while the mean decay rate for MeV was 
3.5%. It should be noted that gender does not affect seropositivity (24). Data has shown that lack 
of second dose of MMR can lead to waning of immunity from vaccination among young adults 
(25). As such, implementation of vaccination campaigns to susceptible populations of those 
between the ages of 15-29, has been suggested as a catch-up method (25). 
Side effects of the MMR vaccine may include mild problems such as fever and rash, 
moderate problems including seizure and temporary low platelet count, and severe problems 
including serious allergic reactions, deafness, and permanent brain damage (26). However, the 
MMR vaccine is much safer than actually being infected with MeV and most people who receive 
the MMR vaccine rarely have any of the serious problems mentioned before (26).  
People who are most at risk are those who have defects in cell mediated immunity (12) 
and are immunocompromised. Unvaccinated children have the highest risk of MeV. Populations 
that suffer from malnutrition and lack adequate healthcare have MeV cases with mortality rates 
up to 10% (4). MeV is still common in underdeveloped and developing countries, such as parts of 
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Asia and Africa. More than 95% of MeV-related deaths occur in countries that have low per capita 
incomes (4). Thus, it is important to monitor immunization coverage of individuals who are 
travelling or immigrating to the US and for those who are travelling out of the US (16).  
Many developing countries do not have access to state-of-the-art medical devices to be 
able to accurately and rapidly screen people in outbreak settings (27). It is important to address 
the absence of proper medical technology that the majority of the world’s population lacks. Many 
of these people have access to poorly resourced healthcare facilities (28) with little to no 
supporting clinical laboratory infrastructure. The development of cheap, easy-to-use, and rapid 
diagnostic assays to test for infectious diseases is paramount to effectively diagnosing and 
treating infected people in low-resource areas. Furthermore, such devices can be used in large 
public settings to rapidly determine immunity. 
Controlling the spread of infectious diseases, such as MeV, in public places such as 
colleges and theme parks is very challenging due to the sheer amount of people that aggregate 
together. Furthermore, such populations of people vary drastically in gender, race, and 
immunization history (29). In college settings, students live, attend, and spend time together in 
close proximity, along with also being very mobile. Many people travel abroad and can acquire 
infectious diseases to bring back, if they lack immunizations (29) or are immunocompromised.  
 Such outbreaks cause significant financial cost (29) to not only the public health 
agencies, but also to the families and medical systems. An evaluation of containment costs 
during the 2008 MeV outbreak in San Diego showed that a strong outbreak response with 95% 
two dose vaccine coverage and absence of vaccine failure resulted in a net public sector cost of 
$10,376 per case, while direct medical charges totaled $1,347 per case (30). Young children who 
could not be vaccinated had to be quarantined, costing families an average of $775 per child (30). 
With such a high cost associated with containing and eliminating MeV in an outbreak situation, it 
is more worthwhile and cost effective to actively determine immunity amongst populations rather 
than attempting to rapidly vaccinate everyone.  
For example, outbreaks in college campuses cause significant disruption to young adults’ 
lives as it impedes their studies and livelihoods. A large MeV outbreak at Washington State in 1995 
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cost the Department of Health and the institution over $400,000 (31). Previous studies have shown 
that US colleges and universities that required prematriculation immunization requirements (PIRs) 
reported less MeV cases and outbreaks compared to colleges and universities that did not require 
PIRs (32). In this study, the fourteen schools that reported MeV outbreaks did not have any state 
regulations or require any PIRs for students. Less than 40% of Washington colleges and 
universities require PIRs and more than 60% of these universities allow exemptions for medical, 
religious, and/or philosophical reasons (31). Less than 60% of US colleges retain immunization 
information for students, which means that there could be a potentially under-vaccinated population 
susceptible to MeV (31) residing in close proximity. Self-reporting of immunizations are not very 
reliable and can lead to under-reporting of vaccinations (33), making rapid determination of 
immunity even more important in not only outbreak settings, but also in large public institutions. 
The gold standard method to test for MeV immunity is the plaque neutralization test 
(PRNT), which measures functional neutralizing Abs (34). This assay is quantitative and requires 
a serum dilution less than 1:120 that reduces the number of plaques by 50% (PRNT titre) in order 
to have a level of Ab protection against MeV (34). PRNT detects all isotypes of Abs directed 
against MeV. PRNT can take up to seven days to complete and it is an assay that is sometimes 
difficult to standardize. In comparison, MeV IgG ELISA’s are very easy and rapid to perform (34), 
but only detect IgG specific for MeV. 
Current diagnostic methods of detecting MeV Abs include indirect MeV commercial 
immunoglobulin M (IgM) capture assays and immunoglobulin G (IgG) capture assays. IgM Abs 
are produced in the event of exposure to a disease, such as MeV. IgM serology is the standard 
for laboratory diagnosis of MeV and commercial IgM immunoassay (EIA) kits are used for 
determination of presence of IgM Abs. IgG Abs are produced after long term immunity is 
developed and is an indicator of past exposure to disease. Commercial IgG EIA kits are used for 
determination of immunity through detection of IgG Abs. 
Four commercial IgM capture assays (Behring, Clark, Gull, and PanBio) were evaluated 
to determine their ability to detect MeV-specific IgM Abs. 308 serum samples from patients 
involved in a MeV outbreak and 454 serum samples from healthy subjects without MeV were 
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screened. Comparison of these four assays determined that they have detection rates between 
57% to 80% and sensitivities that range from 82.8% to 88.6% (2). Most indirect MeV commercial 
IgM assays measure reactivity against the N antigen as Abs to N predominate and appear early 
during infections. The N antigen is a major target of the T-cell response that is needed for viral 
clearance (35). These assays also have routine false-negative and false-positive results (2), 
which poses a problem when trying to rapidly test multiple MeV cases to detect the presence of 
MeV. 
Various commercial IgG ELISA kits are available and can measure reactivity against the 
N antigen or cell culture grown native virus antigens. Two such assays (Microimmune and Dade 
Behring), one using recombinant N antigen and the other using cell culture grown native virus 
antigens, were evaluated for MeV immunity testing (34). Data showed that both ELISA’s has 
similar performance characteristics and provided false negative results in 10% of serum samples 
(34). Both ELISA’s showed a sensitivity of 89.6% with a specificity of 100%.  
A commercially available Diamedix Immunosimplicity® Measles IgG test kit (Diamedix 
Corporation, Miami, Fl) has been shown to have 91.1% sensitivity and 93.8% specificity (36) at a 
PRN cut off of 120. This Diamedix enzyme immunoassay (EIA) test detects Abs to MeV antigen, 
a purified extract of Vero cells infected with Edmonston strain of MeV (37). Previous studies have 
shown that this EIA test has very low sensitivity in detecting MeV Ab at low levels, making it 
unreliable for MeV vaccine-related studies (36). This EIA kit has been shown to have a positive 
predictive value of 99.5% and a negative predictive value of 45.5% on the basis of a PRN titer of 
8, the lowest detectable Ab level by the plaque reduction neutralization test, and have a positive 
predictive value of 88.7% and a negative predictive value of 90.9% on the basis of a PRN titer of 
120, indicating the possibility of false positive results (36). For the purposes of this study, the 
Diamedix Immunosimplicity® Measles IgG test kit was used to screen the same serum samples 
as was used for the RAPID ELISA. 
Rapid antigenic protein in situ display ELISA (RAPID ELISA) will be utilized for protein 
expression and serological analysis. This alternative method for detecting Abs in sera across all 
MeV antigens will allow for a more sensitive high-throughput serologic screening (38) using cDNA 
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fused to GST-tags which will be expressed in situ using in vitro transcription/translation (IVTT) 
with human cell lysate. High sensitivity and reproducibility are the most important advantages 
associated with the RAPID ELISA assay (38).  RAPID ELISAs are also cost-effective; a 96-well 
plate costs $59.11, with each well costing $0.62. In contrast, enzyme-linked immunosorbent 
assays (ELISAs) are limited because these assays require the use of known antigens and a priori 
protein purification (38).  
 
2. MATERIALS AND METHODS 
2.1 Primer Design, PCR, and DNA Purification 
 Primers specific for N, F, and H were designed using attB sites. Genes were amplified 
from measles plasmid, pB(+)MeVvac2(ATU)P, through PCR and run through a 1% agarose gel. 
DNA collected from the PCR reactions was purified using a QIAquick® PCR Purification Kit 
(Qiagen Sample and Assay Technologies, Hiden, Germany). 
 
2.2 Subcloning Into pDONR221 Vector and pJFT7_nGST Vector 
 PCR product was recombined with the Gateway pDONR 221 entry vector through a BP 
reaction to generate an entry clone. The entry clone was recombined with the Gateway-
compatible pJFT7_nGST expression vector, obtained from the DNASU Plasmid Repository at the 
Biodesign Institute at Arizona State University, through LR reactions to generate N-terminal GST 
fusion proteins. 
 
2.3 Detection of MeV Abs Using Expressed Antigens on the Rapid Antigenic Protein in situ 
Display (RAPID) ELISA Platform   
Wells in a 96-well plate were coated with anti-GST antibody and blocked with 5% milk 
PBST 0.2%. GST-tagged proteins were expressed from cDNA using in vitro 
transcription/translation (IVTT) with Hela reagents and human cell lysate. GST-tagged proteins 
were captured onto the anti-GST, washed, and incubated with Mouse anti-GST primary antibody 
diluted to 1:3000. Wells were washed and incubated with Mouse anti-GST primary antibody 
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diluted to 1:3000 and then with sheep anti mouse IgG secondary antibody diluted to 1:6250. 
SuperSignal ELISA Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, Illinois) was 
used for detection (39) and luminesce was detected using Glomax 96 Microplate Luminometer 
(Promega, WI). 
Serum samples from healthy subjects were screened for MeV-specific Abs and to 
determine frequency of seropositivity using the RAPID ELISA system. 
After expression, GST-tagged proteins were captured onto the anti-GST coated wells, 
washed, and incubated with serum samples diluted to 1:3000. Wells were subsequently washed 
and incubated with sheep anti mouse IgG secondary antibody diluted to 1:6250. SuperSignal 
ELISA Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, Illinois) was used for 
detection (39) and luminesce was detected using Glomax 96 Microplate Luminometer (Promega, 
WI). 
 
2.5 Detection of MeV-specific Abs using Diamedix Immunosimplicity® Measles IgG Test 
Kit 
Serum Ab detection using the Diamedix Immunosimplicity® Measles IgG test kit was 
performed as described in the package insert (37).  A 1:101 dilution of serum samples was 
prepared using the Sample Diluent provided in the kit. Serum samples, along with 100 μl of 
provided Calibrator and provided Controls were added to their respective wells in the provided 
96-well plate. Plate was incubated at room temperature for 30 min and then washed with Wash 
Solution 3 times. 100 μl of provided Conjugate was added to all of the wells and then plate was 
incubated at room temperature for 30 min and washed as before. 100 μl of Substrate Solution 
was added to all wells and plate was again incubated at room temperature for 30 min. 100 μl of 
Stop Solution was added and absorbance was detected and quantified using Glomax 96 
Microplate Luminometer (Promega, WI). 
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3. RESULTS 
3.1 Rapid Antigenic Protein in situ Display ELISA for Protein Expression 
 Three full-length proteins (N. F, and H) fused to n-terminal GST protein were tested for 
protein expression. All three antigens were strongly expressed, captured and displayed, as 
detected with an anti-GST antibody. Proteins were expressed, with RLU values ranging between 
3.01 x 109 and 1.20 x 109 (Figure 2). N had an average RLU value of 3.01 x 109 (p<0.001) while 
F had an average RLU value of 1.24 x 109 (p<0.001). H had average RLU value of 1.20 x 109 
(p<0.001). Average RLU value for the negative control was 4.56 x 106 RLU, indicating that N, F 
and H expressed at least 50% greater than the control. There was over an 8-fold improvement in 
expression levels using N-terminal GST fusion proteins. 
 
Figure 2. Protein Expression of N, F, and H antigens. 
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3.2 Frequency distribution of serum samples screened using GST control 
 93% (40/43) of the serum samples from healthy donors and the positive control and 
calibrator screened using GST control had average RLU values that fell between +/- 1 SD of the 
mean for the whole sample set (Figure 3), indicating normal distribution with values that had 
negligible variation. The z-score is defined as the number of standard deviations each value is 
from the mean. The mean of the RLU values across all of the samples screened was 2.65x108, 
while the standard deviation was 1.68x108.  
All average RLU values for serum samples screened were below 1x109. Similar patterns 
of detection have been seen in previous studies using GST control plates/wells as well, indicating 
that current average RLU values are consistent with normal detection rates. No extreme outlier 
was detected within this sample set. Samples 35 and 31 had the highest RLU averages of 
9.21x108 and 8.61x108, respectively. Sample 32 had the lowest RLU average of 1.12x108. The 
minimum and maximum RLU averages fall within the range of of what has been seen in previous 
studies.  
 
Figure 3. Frequency Distribution of Average RLU Values of Serum Samples Screened using 
GST Control 
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3.3 Detection of MeV-specific Abs in Patient Serum using Rapid Antigenic Protein in situ 
Display ELISA 
 N, F, and H were screened across 40 serum samples from healthy subjects and the GST 
ratios were calculated. N, in general, had higher GST ratios, as compared to F and H. It was 
assumed that majority of sera was positive for MeV-specific Abs, as MMR vaccinations are 
required. Cutoff values for N, F, and H, were calculated as the mean +3 standard deviations of 
the GST ratios as observed among the samples screened. Cutoff values for N, F, and H were 
1.21, 1.92, and 1.23 (mean+3SD of negative control), respectively. Based on this criterion, 36 of 
the 40 positive serum samples had GST ratios above the cutoff values, indicating significant 
detection of MeV-specific Abs. 
The calibrator, positive control, and negative control from the Diamedix kit were also 
screened for comparison purposes. The calibrator and positive control had had GST ratios above 
the cutoff values mentioned above for all three antigens, while the negative control had GST 
ratios well below the cutoff values for all three antigens.  
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Figure 4.  Average GST Ratios for Serum Samples Screened Across N, F, and H Antigens. 
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3.4 Detection of MeV-specific Abs in Patient Serum using Diamedix Immunosimplicity® 
Measles IgG test kit 
ELISA UNITS/ml (EU/ml), standardized using provided references which includes the 
calibrator, were calculated in order to determine the potency of immunologically active substance 
in the serum samples that were screened. EU/ml was determined as reactivity in this assay for 
the particular antigen and is expressed per unit volume equal to one milliliter. EU/ml for each 
serum sample was calculated by using the following formula: [(EU/ml of Calibrator/Absorbance of 
Calibrator) x Absorbance of Sample]. Reference ranges were provided in the package insert, and 
any sample with an EU/ml above 20.0 was considered to be reactive (positive) for anti-MeV IgG 
and presumed to have immunity against MeV. Any sample with an EU/ml below 15.0 was 
considered to be nonreactive (negative) for anti-MeV IgG and presumed to be non-immune to 
MeV. The magnitude of the measured result, above the cut-off, is not indicative of the total 
amount of antibody present. The magnitude of the reported IgG level cannot be correlated to an 
endpoint titer. 
The Diamedix test kit presented results that indicated that samples 1-40 were reactive 
(positive) and had MeV-specific Abs present; indicating presumed immunity to MeV. These 
samples had EU/ml that were above the cut-off value of 20.0 EU/mL, and ranged between 46.58 
EU/ml and 126.75 EU/mL. The calibrator had an EU/ml of 100, while the positive control had an 
EU/ml of 76.42. The negative control was shown to be nonreactive, or negative, for MeV-specific 
Abs, with an EU/ml of 5.608.  
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Figure 5.  EU/ml (ELISA Units/ml) of Serum Samples Screened Using the Diamedix 
Immunosimplicity® Measles IgG Test Kit. 
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4. DISCUSSION 
 The highly contagious nature of MeV makes rapid diagnostic analysis crucial during 
outbreaks (18). Before the MMR vaccine was implemented globally, MeV caused over 2.6 million 
deaths every year (4). People who are most at risk are unvaccinated children, pregnant women, 
and non-immune people (4). 2014 had over 20 outbreaks of MeV cases, constituting about 89% 
of all reported cases (6). Due to the contagious nature of MV and its ability to live for up to two 
hours in an area where an infected person has coughed or sneezed, it is imperative that there are 
measures put in place in order to ensure the safety of the general public. A person infected with 
MeV can infect 90% of the people they come into contact with if those people are not vaccinated 
(15).  
MeV genes of interest were successfully subcloned into the Gateway entry vector, 
pDONR 221, and Gateway expression vector, pANT7_cGST (from previous studies) and 
pJFT7_nGST. This was confirmed through sequence analysis using Sequencher 5.0 (Gene 
Codes Corporation, Ann Arbor, Michigan). Subcloned MeV genes of interest were tested for 
protein expression and three of them successfully expressed at least 50% greater than the 
control, ensuring that all MeV fusion proteins could be used serologic analysis. N had the 
strongest expression, while F and H had weaker expression. There was over an 8-fold 
improvement in expression levels using N-terminal GST fusion proteins, indicating that these 
fusion proteins were suitable for serum screening. Protein expression levels can vary, but 
significant protein expression has been seen to range above 1x109 from previous studies.  
A programmable ELISA assay, termed RAPID ELISA, was developed using three 
antigens from the MeV genome for serologic detection of MeV-specific Abs. RAPID ELISAs have 
been used in previous studies to detect p53-Autoantibodies (AAbs) for use as prognostic 
biomarkers and have been shown to detect higher frequency of p53-specific AAbs, as compared 
to published reports (40). 
From a small sample set (40 serum samples from healthy donors) that was used to 
screen N, F and H antigens, it could be seen that most MeV-specific Abs were directed against 
the N antigen. This data shows that MeV-specific antibodies in sera can be detected at significant 
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levels, using all three antigens. Additionally, the absence of MeV-specific antibodies can also be 
detected, as seen with the low GST ratio for the negative control that was provided with the 
Diamedix test kit. Cutoff values for positive serology was defined as the mean +3 standard 
deviations of the GST ratio observed among the set of samples screened. Calibrator, positive 
control, and negative control provided in the Diamedix Immunosimplicity® Measles IgG test kit 
was also screened using this platform. The negative control, which was non-reactive for MeV IgG 
Abs, had very low detection (37) with GST ratios well below the cutoff values for all three 
antigens. The calibrator, which was highly reactive for MeV IgG Abs (37), had high GST ratios 
above the cutoff values, while the positive control, which was moderately reactive for MeV IgG 
Abs (37), also had GST ratios above the cutoff values.  
Evaluation of the combination of three antigens showed that, of the 40 serum samples 
that were screened, 36 had detection of IgG to N, F, and/or H, greater than the cutoff values, 
indicating good signal strength and detection levels. Because this assay uses IVTT with human 
cell lysate to generate the production of fusion proteins, there can be differences in protein folding 
and structure. Furthermore, it might be beneficial to excise the transmembrane region of the H 
and F antigens, as that might be affecting protein folding and inhibiting proper Ab capture. 
Currently, this assay has not been tested using a large sample of negative controls. 
To ensure that GST control had normal distribution with negligible variation across all of 
the serum samples that were screened, z-scores were calculated and it was determined that 93% 
(40/43) of the samples had average RLU values that fell between +/- 1 SD of the sample mean. 
As expected, all average RLU values for serum samples screened were below 1x109 and similar 
patterns of detection were seen between this study and previous studies using GST control 
plates/wells. This data indicates that GST control plates had a range of similar values across all 
serum samples that were screened and no large outliers were detected. 
Samples tested using the Diamedix Immunosimplicity® Measles IgG test kit had EU/ml 
greater than the cutoff value of 20.0 EU/ml, indicating that all of the samples had detectable 
levels of MeV-specific Abs, which was expected. Comparisons between the two assays show 
similar detection patterns, with the exception of four samples which fell below the cutoff values for 
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all three antigens on the RAPID ELISA platform. Samples 10, 18, 25, and 31 had GST ratios that 
fell below the cutoff values calculated for each antigen. Consequently, these four samples also 
had higher average RLU values for GST control, as compared to the other serum samples. GST 
ratios may have been lower due to high background for these samples. For further studies, it will 
be necessary to optimize the background signal to lower it and to determine concentration of Abs 
and serum that will be needed for optimal signal detection.  
The Diamedix kit had better detection of MeV-specific Abs in serum, as compared to the 
RAPID ELISA platform, which may be due to the fact that this kit detects Abs to the whole MeV 
antigen, which is a purified extract of Vero cells infected with Edmonston strain of MeV (37). It 
may be beneficial to create custom protein microarrays using Vero cells infected with Edmonston 
strain of MeV and screen serum samples to see if better detection is achieved, as compared to 
the three antigen RAPID ELISA platform. Using the entire MeV antigen could prove to overcome 
some of low detection that was seen with some samples and allow for better Ab capture, as the 
entirety of the antigen can be spotted onto these arrays. For further studies, it may be extremely 
advantageous, in terms of moving forward with a point of care assay, to test for MeV immunity 
using custom protein microarrays spotted with the whole MeV antigen.  
A large weakness of this study is the lack of negative samples used for serologic 
screening. Sensitivities and specificities could not be determined for this present study as 
negative cases and controls were not screened due to accessibility issues. For an assay to be 
clinically useful, it would be necessary to have very high specificity, indicating lower numbers of 
false positives, and significantly high sensitivity as well. Most IgM MeV assays have reported 
sensitivities between 83-89% and specificities of 95-100% (41). Current IgG MeV assays have 
sensitivities that range from 70-88% and specificities of 99-100%, making it necessary for any 
new IgG assays to have comparable rates in order to be as clinically useful. Limitations 
associated with using the RAPID ELISA platform for MeV IgG testing include potential false 
negative results, as indicated by the four samples that had very low detection using this assay. 
The probability of false positive results cannot be determined at this time. 
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The RAPID ELISA platform has many strengths, including the ability to screen a large 
number of clinical samples against a limited number of proteins. Furthermore, antigens are 
readily expressed as full length N-terminal GST tagged fusion proteins that are captured onto the 
96-well plates using anti-tag Abs. This method eliminates the need to amplify sequences by PCR 
and to prepare quantified plasmid DNA for screening processes as recombinant proteins can be 
captured in situ using anti-tag Abs. A large advantage of the RAPID ELISA platform is the ease 
and flexibility of using cDNA as source antigens without having to separately express and purify 
them. Because of this, antigens can also very readily be printed on custom microarrays for point 
of care testing. From previous studies, it is already known that the sensitivity of detection for the 
RAPID ELISA platform is comparable to standard ELISAs. 
This current study needs to be expanded to include a larger sample set with negative 
cases and controls that can be used to accurately determine the sensitivity and specificity of the 
RAPID ELISA platform. A large limitation to this present study was the fact that only positive 
serum samples were available, making it harder to determine if the RAPID ELISA platform could 
also detect the absence of MeV-specific Abs. For further studies, pre- and post-vaccination sera 
will need to be screened in order to accurately ascertain the validity and strength of using the 
RAPID ELISA platform for rapid determination of MeV immunity.  
Though the RAPID ELISA system was weaker than the standard Diamedix kit, with 
proper optimization and testing of a larger sample set, this assay can be used for point of care 
testing. The ability to rapidly detect MeV-specific immunity is extremely important so that 
individuals that are susceptible and need to be vaccinated/treated can be rapidly identified in 
outbreak settings. Real time determination of vital information about individuals being tested can 
significantly increase outbreak containment and elimination procedures (42). Such assays can 
help facilitate rapid diagnosis in countries where resources are limited, aiding in MeV surveillance 
and treatment response time. In addition, implementation of such assays in public areas with high 
traffic, such as amusement parks and airports, can also help rapidly screen the thousands of 
people traveling from various areas of the world in order to ensure the general public is not being 
exposed to the virus. The main objective of a point-of-care assay is to generate a rapid result so 
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that appropriate treatment can be administered, leading to an improved clinical and economic 
outcome (43). 
A rapid point-of-care assays can be used for personal testing, at the scene of an 
accident/outbreak, in hospitals, and in underdeveloped countries. Such implementation of point-
of-care assays can completely revolutionize health care delivery. Having a point-of-care assay 
can also help with disaster recovery in ensuring emergency preparedness. Furthermore, there is 
a national laboratory technologist shortage, with a projected need for 13,000 technologists every 
year (42), making it significantly harder to have and to use large and complex machinery for 
laboratory diagnosis. Studies have shown that point-of-care devices can reduce hospital stay, 
improve adherence to treatment, and reduce complications that might arise (43). 
In conclusion, this study shows that all of the expressed single MV genes were able to 
capture IgG antibodies present in 90% of the serum samples tested using the RAPID ELISA 
platform. Though the RAPID ELISA platform had higher levels of false negative results, as 
compared to the Diamedix Immunosimplicity® Measles IgG test kit, with proper optimization and 
calibration, application of this assay using programmable protein arrays (FLEX NAPPA) 
displaying these antigens for rapid determination of MeV immunity has great potential and 
applicability in the field, for personal use, and in healthcare facilities. 
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